Medicare Enrolled
Dr. Sean Nikravan, MD
Endocrinology · Newport Beach, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Nikravan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Nikravan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Nikravan
Dr. Sean Nikravan is an endocrinology specialist in Newport Beach, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Nikravan performed 3,106 Medicare services across 1,139 unique beneficiaries.
Between the years covered by Open Payments, Dr. Nikravan received a total of $56,554 from 81 pharmaceutical and/or device companies across 1063 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Nikravan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 22% volume in CA
$56,554 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,106
Medicare services
Top 22% in CA for endocrinology
1,139
Unique beneficiaries
$82
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~155 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
851 | $98 | $150 |
| Denosumab injection (Prolia/Xgeva) | 721 | $19 | $36 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
597 | $142 | $250 |
| Continuous glucose monitoring with interpretation This procedure involves monitoring blood sugar levels in tissue fluid using a sensor placed under the skin, along with the interpretation and reporting of the results. |
318 | $29 | $70 |
| Ultrasound of head and neck soft tissue This procedure uses sound waves to create images of the soft tissues in the head and neck area. It allows for the visualization of structures beneath the skin without using radiation. |
253 | $99 | $350 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
91 | $132 | $250 |
| Continuous glucose monitoring, sensor under skin This procedure involves continuous monitoring of blood sugar levels in tissue fluid using a sensor placed under the skin with provider-supplied equipment. |
38 | $135 | $180 |
| Ultrasound guidance for needle placement Use of ultrasound imaging to guide the precise placement of a needle during a medical procedure. |
37 | $52 | $241 |
| New patient office visit, complex (60-74 min) | 36 | $168 | $450 |
| Ultrasound-guided fine needle aspiration biopsy, first lesion A biopsy procedure where a thin needle is used to collect tissue samples from a growth, guided by ultrasound imaging. This code applies to the first lesion or mass sampled during the session. |
34 | $119 | $350 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
29 | $140 | $200 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
21 | $13 | $115 |
| Ultrasound of arm and leg arteries A non-invasive imaging test that uses sound waves to examine the blood vessels in the arms and legs. It evaluates blood flow and checks for blockages or other vascular issues. |
21 | $117 | $170 |
| Autonomic nervous system function test This test evaluates how well the sympathetic nervous system is functioning. It assesses the automatic control of bodily processes such as heart rate and blood pressure. |
20 | $112 | $160 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
20 | $12 | $27 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
19 | $78 | $175 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$56,554
Total received (2018-2024)
Avg $8,079/year across 7 years
Top 7% in CA for endocrinology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
81
Companies
1,063
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$20,867 (36.9%)
Other
Charitable contributions, space rental, and other categories
$19,312 (34.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,375 (29.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$8,931
2023
$9,125
2022
$9,899
2021
$2,724
2020
$1,209
2019
$6,362
2018
$18,304
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Cambridge Interventional LLC
$6,000
Antares Pharma, Inc.
$419
Amgen Inc.
$294
Lilly USA, LLC
$286
Abbott Laboratories
$259
Ascendis Pharma Inc
$215
BETA BIONICS, INC.
$208
RECORDATI_RARE_DISEASES_INC.
$157
ABBVIE INC.
$138
Insulet Corporation
$118
Novo Nordisk Inc
$102
Corcept Therapeutics
$70
Dexcom, Inc.
$65
Boehringer Ingelheim Pharmaceuticals, Inc.
$59
Otsuka America Pharmaceutical, Inc.
$46
Xeris Pharmaceuticals, Inc.
$45
Ascensia Diabetes Care Us Inc.
$43
Verity Pharmaceuticals Inc.
$41
Novartis Pharmaceuticals Corporation
$40
Boston Scientific Corporation
$37
Acella Pharmaceuticals, LLC
$37
SANOFI-AVENTIS U.S. LLC
$35
Kyowa Kirin, Inc.
$29
AstraZeneca Pharmaceuticals LP
$27
CeQur Corporation
$25
SHIELD THERAPEUTICS INC
$20
Alexion Pharmaceuticals, Inc.
$19
Sumitomo Pharma America, Inc.
$19
Exact Sciences Corporation
$16
Phathom Pharmaceuticals, Inc.
$16
Tolmar, Inc.
$15
Embecta Corp.
$15
Medtronic, Inc.
$15
Top 3 companies account for 75.2% of 2024 payments
All-time payments by company (2018-2024) ›
Cambridge Interventional LLC
$19,312
Janssen Pharmaceuticals, Inc
$13,494
AbbVie, Inc.
$7,334
Antares Pharma, Inc.
$2,213
Amgen Inc.
$1,793
Lilly USA, LLC
$1,493
Abbott Laboratories
$974
Corcept Therapeutics
$742
Boehringer Ingelheim Pharmaceuticals, Inc.
$568
MannKind Corporation
$528
AstraZeneca Pharmaceuticals LP
$445
Horizon Therapeutics plc
$419
Novo Nordisk Inc
$397
Dexcom, Inc.
$380
ABBVIE INC.
$362
SANOFI-AVENTIS U.S. LLC
$351
Otsuka America Pharmaceutical, Inc.
$331
RECORDATI_RARE_DISEASES_INC.
$292
Xeris Pharmaceuticals, Inc.
$278
Mannkind Corporation
$278
Insulet Corporation
$275
Ascendis Pharma Inc
$272
IBSA Pharma Inc.
$219
AbbVie Inc.
$209
BETA BIONICS, INC.
$208
Radius Health, Inc.
$179
CeQur Corporation
$160
ARBOR PHARMACEUTICALS, INC.
$153
Pharming Healthcare, Inc.
$152
Novartis Pharmaceuticals Corporation
$144
Medtronic MiniMed, Inc.
$143
Shire North American Group Inc
$137
Alexion Pharmaceuticals, Inc.
$137
Supernus Pharmaceuticals, Inc.
$134
Philips Electronics North America Corporation
$129
Shield Therapeutics Inc
$126
Tolmar, Inc.
$120
Ascensia Diabetes Care Us Inc.
$96
Azurity Pharmaceuticals, Inc.
$80
Acella Pharmaceuticals, LLC
$73
Gemini Laboratories, LLC
$73
Medtronic, Inc.
$73
Lumenis, Inc
$71
TOLMAR Pharmaceuticals, Inc.
$71
Amneal Pharmaceuticals LLC
$61
Bayer HealthCare Pharmaceuticals Inc.
$55
Exact Sciences Corporation
$53
Bayer Healthcare Pharmaceuticals Inc.
$49
Biohaven Pharmaceutical Holding Company Ltd.
$49
Aegerion Pharmaceuticals, Inc.
$49
GRT US Holding, Inc.
$47
Tandem Diabetes Care, Inc.
$45
Amryt Pharma Holdings Ltd
$44
Verity Pharmaceuticals Inc.
$41
EUSA Pharma (US) LLC
$40
Acerus Pharmaceuticals Corporation
$38
Boston Scientific Corporation
$37
Arbor Pharmaceuticals, Inc.
$36
Biohaven Pharmaceuticals, Inc.
$34
Alfasigma USA, Inc.
$33
Ultragenyx Pharmaceutical Inc.
$30
Kyowa Kirin, Inc.
$29
Bigfoot Biomedical Inc
$29
Ascensia Diabetes Care US Inc.
$29
Averitas Pharma Inc.
$27
BioMarin Pharmaceutical Inc.
$22
Lucid Diagnostics Inc.
$22
Nevro Corp.
$22
Medtronic USA, Inc.
$21
Senseonics, Incorporated
$21
Eisai Inc.
$21
Janssen Biotech, Inc.
$21
SHIELD THERAPEUTICS INC
$20
Sumitomo Pharma America, Inc.
$19
Optos, Inc.
$18
Phathom Pharmaceuticals, Inc.
$16
Embecta Corp.
$15
Valeritas, Inc.
$15
Currax Pharmaceuticals LLC
$13
Takeda Pharmaceuticals U.S.A., Inc.
$13
Retrophin, Inc.
$1
Top 3 companies account for 71.0% of all-time payments
Associated products mentioned in payments ›
(820) Cholbam · (8874) inCourage · ABILIFY MAINTENA · ACCRUFER · AFREZZA · Aimovig · Androgel · BAQSIMI · BASAGLAR · BD Nano 2nd Gen Pen Needle · CINRYZE · CONTRAVE · CRF · CRYSVITA · CeQur Simplicity · Cologuard Collection Kit · Contour Next · Crysvita · DEXCOM CGM · DEXCOM G6 CGM SYSTEM · Dayvigo · Dexcom CGM · Dexcom G6 Transmitter · ELIGARD · ETERNA · EVENITY · EVERSENSE E3 SENSOR KIT - RETAIL · Edarbi · Edarbyclor · Eversense · FARXIGA · FENSOLVI · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FreeStyle Libre · FreeStyle Libre blood glucose Flash Monitoring System · GEMTESA · GVOKE HYPOPEN · GVOKE PFS · HUMALOG · HUMULIN · Horizant · INVOKANA · ISTURISA · JARDIANCE · JATENZO · JYNARQUE · KEVEYIS · Kerendia · Korlym · LEQVIO · LICART · LYUMJEV · Lumenis Pulse 120H · MINIMED 770G · MINIMED 780G · MOUNJARO · MYALEPT · MYCAPSSA · Minimed 670G System · NATPARA · NOCDURNA · NP Thyroid 60 · NURTEC ODT · Natesto · OTREXUP · Omnia · Omnipod · Otrexup · Ozempic · P200DTx · PRALUENT · Prolia · QUTENZA · Qutenza · RECORLEV · RUCONEST · Repatha · Rybelsus · S&RC Und · SIGNIFOR LAR · SIMPONI · SKYTROFA · SOLIQUA · SOLIQUA 100/33 · STRENSIQ · SYNTHROID · Saxenda · Skytrofa · Sogroya · Strensiq · Sylvant · Synthroid · TEPEZZA · TLANDO · TOUJEO · TRADJENTA · TRULICITY · TZIELD · Tirosint · Tlando · Triptodur · Tymlos · UBRELVY · UNITHROID · UNITY DIABETES MANAGEMENT SYSTEM · V-GO · VECTRIS · VOQUEZNA · Victoza · WaveWriter Alpha Prime 16 · Wegovy · XARELTO · XYOSTED · iLet Bionic Pancreas · t-slim insulin pump
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (37%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in endocrinology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 7% for endocrinology in CA.
Geographic Context
Endocrinologists within 10 mi
119
Per 100K population
3.8
County median income
$113,702
Nearest hospital
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Nikravan is a clinical cardiology specialist, with above-average Medicare volume (top 22% in CA), with mixed engagement industry engagement in the top 7% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Nikravan experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Nikravan performed 851 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Nikravan receive payments from pharmaceutical companies?
Yes. Dr. Nikravan received a total of $56,554 from 81 companies across 1,063 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Nikravan's costs compare to other endocrinologists in Newport Beach?
Dr. Nikravan's average Medicare payment per service is $82. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Nikravan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Endocrinology
Common procedures, typical costs, and what industry payments mean in endocrinology.
Same specialty & city
Endocrinologists in Newport Beach
Browse endocrinologists in Newport Beach ranked by procedure volume and transparency data.
Highest volume
Top Endocrinologists in CA
Endocrinologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Endocrinologists in CA
Which CA endocrinologists receive the most from drug and device companies.
By company
Cambridge Interventional LLC Payments to Doctors
See all physicians who received payments from Cambridge Interventional LLC.
By company
Janssen Pharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Janssen Pharmaceuticals, Inc.
By company
AbbVie, Inc. Payments to Doctors
See all physicians who received payments from AbbVie, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology